Last edition
News about "liver and cardiometabolic diseases"
Roche to Acquire 89bio in Deal Worth Up to USD 3.5 Billion
Roche has entered into a merger agreement to acquire 89bio, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases.
Liver And Cardiometabolic Diseases | 18/09/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members